1)Fourrier C, Singhal G, Baune BT:Neuroinflammation and cognition across psychiatric conditions. CNS Spectr 24:4-15, 2019
2)Uhlhaas PJ, Singer W:Abnormal neural oscillations and synchrony in schizophrenia. Nat Rev Neurosci 11:100-113, 2010
3)Hindmarch I:Cognitive toxicity of pharmacotherapeutic agents used in social anxiety disorder. Int J Clin Pract 63:1085-1094, 2009
4)Huhtaniska S, Jaaskelainen E, Heikka T, et al:Long-term antipsychotic and benzodiazepine use and brain volume changes in schizophrenia:The Northern Finland Birth Cohort 1966 study. Psychiatry Res Neuroimaging 266:73-82, 2017
5)Federico A, Tamburin S, Maier A, et al:Multifocal cognitive dysfunction in high-dose benzodiazepine users:a cross-sectional study. Neurol Sci 38:137-142, 2017
6)Kitajima R, Miyamoto S, Tenjin T, et al:Effects of tapering of long-term benzodiazepines on cognitive function in patients with schizophrenia receiving a second-generation antipsychotic. Prog Neuropsychopharmacol Biol Psychiatry 36:300-306, 2012
7)兼田康宏,住吉太幹,中込和幸:統合失調症認知機能簡易評価尺度日本語版(BACS-J).精神医学 50:913-917, 2008
8)Baandrup L, Fagerlund B, Glenthoj B:Neurocognitive performance, subjective well-being, and psychosocial functioning after benzodiazepine withdrawal in patients with schizophrenia or bipolar disorder:a randomized clinical trial of add-on melatonin versus placebo. Eur Arch Psychiatry Clin Neurosci 267:163-171, 2017
9)Takita Y, Takaesu Y, Ono K, et al:Association between the high-dose use of benzodiazepines and rehospitalization in patients with schizophrenia:a 2-year naturalistic study. Neuropsychiatr Dis Treat 12:3243-3247, 2016
10)日本神経精神薬理学会:統合失調症薬物治療ガイドライン.医学書院,pp108-112, 2016